Studies on protective immunity against malaria

疟疾保护性免疫研究

基本信息

  • 批准号:
    62570171
  • 负责人:
  • 金额:
    $ 1.09万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 财政年份:
    1987
  • 资助国家:
    日本
  • 起止时间:
    1987 至 1988
  • 项目状态:
    已结题

项目摘要

1. Mechanisms of acquisition of protective immunity against malaria was investigated by comparative studies on infections with virulent plasmodium berghei (Pb NK65) and its attenuated derivative (Pb XAT) in mice. In Pb NK65 infection, mice showed suppressive response in antibody production and delayed-type hypersensitivity and development of auto antibodies against lymphocytes. Mice infected with Pb XAT did not show these responses but developed solid protective immunity against Pb NK65 infection accompanied with high antibody titer. When such an immune serum was transferred into mice Pb XAT infection was eliminated completely. These results showed that Pb XAT stimulates antibody production which contributes protection against the parasites. On the contrary, in Pb NK65 infection harmful immunopathological responses against host are more prominent than protective immune responses against the parasites. 2. Role of T cells in two aspect of immunity to Pb was examined in mice by administration of monoclonal antibodies (MAB) against T cell subsets or lymphokines. First, mice treated with anti Lyt. 2 mAb showed significantly longer survival from infection with Pb NK65 compared with intact or anti L3T4 mAb administration. This phenomenon was also observed in mice by treatment with anti gamma-IFN mAb. second, in Pb XAT infection, administration with either anti L3T4 or anti gamma-IFN mAb precluded induction of protective immunity. These findings reveal that CD4^+ T cells might be responsible for protection and CD8^+ T cells for immunopathology of the infected hosts and gamma-IFN must be effector molecules in both immune responses.
1.通过对伯氏疟原虫强毒株(Pb NK 65)及其减毒衍生物(Pb XAT)感染小鼠的比较研究,探讨了小鼠获得抗疟保护性免疫的机制。在铅NK 65感染,小鼠表现出抑制反应的抗体产生和迟发型超敏反应和发展的自身抗体的淋巴细胞。感染Pb XAT的小鼠没有表现出这些反应,但对Pb NK 65感染产生了高抗体滴度的保护性免疫。将该免疫血清转移到小鼠体内后,PbXAT感染被完全消除.这些结果表明,铅XAT刺激抗体的产生,这有助于保护免受寄生虫。相反,在Pb NK 65感染中,对宿主的有害免疫病理反应比对寄生虫的保护性免疫反应更突出。2.本文用抗T细胞亚群单克隆抗体(MAB)和抗淋巴因子单克隆抗体(MAB)研究了T细胞在小鼠铅免疫中的两个方面的作用。首先,用抗Lyt治疗的小鼠。与完整或抗L3 T4 mAb给药相比,2 mAb显示Pb NK 65感染的存活时间显著延长。在用抗γ-IFN mAb处理的小鼠中也观察到这种现象。第二,在Pb XAT感染中,施用抗L3 T4或抗γ-IFN mAb排除了保护性免疫的诱导。这些发现表明,CD 4 ^+ T细胞可能负责保护,CD 8 ^+ T细胞可能负责感染宿主的免疫病理学,γ-IFN在这两种免疫应答中一定是效应分子。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
S. Waki: "Acquirement of protective immunity in mice through infection with an attenuated isolate and its failure in parent virulent Plasmodium berghei" Parasitology Research. (1989)
S. Waki:“小鼠通过感染减毒分离株获得保护性免疫力,但在母体伯氏疟原虫中却失败”寄生虫学研究。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Waki,Seiji.: Journal of Immunology.
Waki,Seiji.:免疫学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Takao Takagi & Seiji Waki: Experimental Parasitology.
高木隆雄
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WAKI Seiji其他文献

WAKI Seiji的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WAKI Seiji', 18)}}的其他基金

Development of a new drug sensitivity test for Plasmodium falciparum applicable in the field
开发适用于现场的恶性疟原虫新药敏试验
  • 批准号:
    01044021
  • 财政年份:
    1989
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Grant-in-Aid for international Scientific Research
Studies on malaria immunology
疟疾免疫学研究
  • 批准号:
    01570210
  • 财政年份:
    1989
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Understanding the mechanism of protective immunity against HIV-infection
了解针对 HIV 感染的保护性免疫机制
  • 批准号:
    491103
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Fellowship Programs
Importance of IL-15 responsive CD8+ cells in protective immunity against AIDS viruses
IL-15 反应性 CD8 细胞在针对艾滋病病毒的保护性免疫中的重要性
  • 批准号:
    23K07949
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
PITCH2 - Protective Immunity through T Cells in Healthcare workers 2
PITCH2 - 通过医护人员的 T 细胞实现保护性免疫 2
  • 批准号:
    MR/X009297/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Research Grant
Defining the role of monocytes in protective immunity against healing and non-healing Leishmaniasis: implications for treatment and vaccination against phagosomal pathogens.
定义单核细胞在针对愈合和非愈合利什曼病的保护性免疫中的作用:对吞噬体病原体的治疗和疫苗接种的影响。
  • 批准号:
    495111
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Operating Grants
Identifying the targets of protective immunity to severe falciparum malaria
确定严重恶性疟疾的保护性免疫目标
  • 批准号:
    10893666
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
MECHANISMS PROGRAMMING PROTECTIVE IMMUNITY FROM RhCMV-SIV VACCINE AND IL-15 ACTIONS
RhCMV-SIV 疫苗和 IL-15 作用的保护性免疫编程机制
  • 批准号:
    10723635
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Type II alveolar epithelial cell-intrinsic IL-1 response in protective immunity against tuberculosis
II 型肺泡上皮细胞内在 IL-1 反应在结核病保护性免疫中的作用
  • 批准号:
    10660267
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Activation of NK cell-mediated protective immunity for the systemic treatment of ALD
激活 NK 细胞介导的保护性免疫以全身治疗 ALD
  • 批准号:
    10453261
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
A Single-dose DNA vaccine platform to safely induce protective immunity against Zika
单剂量 DNA 疫苗平台可安全诱导针对寨卡病毒的保护性免疫力
  • 批准号:
    10026208
  • 财政年份:
    2022
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Small Business Research Initiative
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了